IBDEI2U6 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47599,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,47599,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,47600,0)
 ;;=C88.2^^209^2346^213
 ;;^UTILITY(U,$J,358.3,47600,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47600,1,3,0)
 ;;=3^Heavy Chain Disease
 ;;^UTILITY(U,$J,358.3,47600,1,4,0)
 ;;=4^C88.2
 ;;^UTILITY(U,$J,358.3,47600,2)
 ;;=^55078
 ;;^UTILITY(U,$J,358.3,47601,0)
 ;;=C88.3^^209^2346^235
 ;;^UTILITY(U,$J,358.3,47601,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47601,1,3,0)
 ;;=3^Immunoproliferative Small Intestinal Disease
 ;;^UTILITY(U,$J,358.3,47601,1,4,0)
 ;;=4^C88.3
 ;;^UTILITY(U,$J,358.3,47601,2)
 ;;=^61964
 ;;^UTILITY(U,$J,358.3,47602,0)
 ;;=C88.4^^209^2346^138
 ;;^UTILITY(U,$J,358.3,47602,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47602,1,3,0)
 ;;=3^Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Assoc Lymphoid Tissue
 ;;^UTILITY(U,$J,358.3,47602,1,4,0)
 ;;=4^C88.4
 ;;^UTILITY(U,$J,358.3,47602,2)
 ;;=^5001749
 ;;^UTILITY(U,$J,358.3,47603,0)
 ;;=C88.8^^209^2346^281
 ;;^UTILITY(U,$J,358.3,47603,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47603,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases NEC
 ;;^UTILITY(U,$J,358.3,47603,1,4,0)
 ;;=4^C88.8
 ;;^UTILITY(U,$J,358.3,47603,2)
 ;;=^5001750
 ;;^UTILITY(U,$J,358.3,47604,0)
 ;;=C88.9^^209^2346^282
 ;;^UTILITY(U,$J,358.3,47604,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47604,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases,Unspec
 ;;^UTILITY(U,$J,358.3,47604,1,4,0)
 ;;=4^C88.9
 ;;^UTILITY(U,$J,358.3,47604,2)
 ;;=^5001751
 ;;^UTILITY(U,$J,358.3,47605,0)
 ;;=C90.00^^209^2346^351
 ;;^UTILITY(U,$J,358.3,47605,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47605,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,47605,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,47605,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,47606,0)
 ;;=C90.01^^209^2346^350
 ;;^UTILITY(U,$J,358.3,47606,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47606,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,47606,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,47606,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,47607,0)
 ;;=C90.02^^209^2346^349
 ;;^UTILITY(U,$J,358.3,47607,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47607,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,47607,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,47607,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,47608,0)
 ;;=C90.10^^209^2346^444
 ;;^UTILITY(U,$J,358.3,47608,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47608,1,3,0)
 ;;=3^Plasma Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47608,1,4,0)
 ;;=4^C90.10
 ;;^UTILITY(U,$J,358.3,47608,2)
 ;;=^5001754
 ;;^UTILITY(U,$J,358.3,47609,0)
 ;;=C90.11^^209^2346^443
 ;;^UTILITY(U,$J,358.3,47609,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47609,1,3,0)
 ;;=3^Plasma Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,47609,1,4,0)
 ;;=4^C90.11
 ;;^UTILITY(U,$J,358.3,47609,2)
 ;;=^267517
 ;;^UTILITY(U,$J,358.3,47610,0)
 ;;=C90.12^^209^2346^442
 ;;^UTILITY(U,$J,358.3,47610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47610,1,3,0)
 ;;=3^Plasma Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47610,1,4,0)
 ;;=4^C90.12
 ;;^UTILITY(U,$J,358.3,47610,2)
 ;;=^5001755
 ;;^UTILITY(U,$J,358.3,47611,0)
 ;;=C90.20^^209^2346^137
 ;;^UTILITY(U,$J,358.3,47611,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47611,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,47611,1,4,0)
 ;;=4^C90.20
 ;;^UTILITY(U,$J,358.3,47611,2)
 ;;=^5001756
 ;;^UTILITY(U,$J,358.3,47612,0)
 ;;=C90.21^^209^2346^136
 ;;^UTILITY(U,$J,358.3,47612,1,0)
 ;;=^358.31IA^4^2
